How Long Does SS-31 Stay in Your System? What the Literature Reports

The short answer, stated plainly

The question "how long does SS-31 stay in your system" has two separate parts, and the published literature answers them unevenly. The first part — how long the intact peptide circulates in blood — requires a pharmacokinetic (PK) study with timed plasma sampling. No such human PK trial for SS-31 appears among the verified papers summarised on this page, so no half-life number, no clearance rate and no "time to zero" figure is given here. Any specific hour-count circulating online for SS-31 is not traceable to the studies cited below.

The second part — how long a biological effect persists after the peptide is gone — is a pharmacodynamic question, and the SS-31 literature is largely built around it. A 2022 review in Oxidative Medicine and Cellular Longevity described SS-31 as a mitochondria-targeting peptide and reported that it ameliorated kidney disease across the experimental models it surveyed (PMID 35707274). That distinction — between drug presence and drug effect — organises everything below.

What "stays in your system" actually measures

In pharmacology, "stays in your system" is shorthand for a cluster of measured parameters. A conventional PK study collects blood at fixed intervals after dosing and derives them. A 2012 randomised, open-label, parallel study in healthy male subjects compared a 30 mg modified-release tablet of metoclopramide with 10 mg immediate-release tablets across single and multiple doses, and researchers used exactly this design to characterise the exposure curve (PMID 22328192). That trial studied a small-molecule drug, not SS-31; it is cited here only as an example of how the question is answered experimentally, and none of its numbers transfer to a peptide.

A widely used rule of thumb in pharmacology holds that a compound is approximately 97% eliminated after five elimination half-lives. That arithmetic is only usable when a half-life has actually been measured in the species and route of interest. Without a published SS-31 half-life in the set reviewed here, the five-half-life calculation cannot be applied to SS-31 honestly.

What the compound-specific SS-31 literature does report

The SS-31 papers in this set are mechanistic and preclinical rather than pharmacokinetic. They describe what the peptide did inside cells and tissues, not how long it lingered in blood.

• A 2024 study in the International Journal of Molecular Medicine reported that SS-31 activated mitoGPX4 and alleviated mitochondria-dependent ferroptosis in a diabetic cardiomyopathy context (PMID 39364755).
• A 2021 report in Free Radical Research found that the mitochondrial antioxidant SS-31 attenuated lipopolysaccharide-induced apoptosis and pyroptosis of nucleus pulposus cells by scavenging mitochondrial reactive oxygen species and maintaining the stability of mitochondrial dynamics (PMID 34903138).
• A 2015 paper in Disease Models & Mechanisms reported that a mitochondrial therapeutic reversed visual decline in mouse models of diabetes (PMID 26035391).

None of those three papers is a pharmacokinetic study, and none of them is cited here as one. They establish that the compound has been studied for biological activity in several organ systems; they do not establish a clearance timeline.

Plasma half-life versus target-tissue residence

For compounds that concentrate in a subcellular compartment, plasma measurements can substantially understate how long the molecule remains where it acts. SS-31 is characterised in the literature as mitochondria-targeting, and researchers in the 2022 kidney review framed its activity in terms of accumulation at and interaction with the mitochondrion rather than systemic circulation (PMID 35707274). In such cases, three timelines diverge: the blood timeline, the tissue timeline, and the downstream-biology timeline.

The downstream-biology timeline can be the longest of the three. Reviews of mitochondrial dysfunction describe cascades — redox signalling, calcium handling, organelle turnover — that reset over days rather than hours. A 2025 review in Cells characterised mitochondrial dysfunction as a persistent driver of kidney disease progression rather than a transient event (PMID 40497970), and a 2017 review in Current Heart Failure Reports discussed mitochondrial calcium handling and reactive oxygen species as ongoing therapeutic targets in heart failure (PMID 28656516). A biological process that unfolds over that timescale will not track a plasma concentration curve.

General peptide pharmacokinetics — labelled as general, not SS-31 data

The following points come from peptide pharmacology as a field, not from measurements of SS-31. They are included so the shape of the unknown is clear, and they should not be read as SS-31 findings:

• Short peptides are generally susceptible to enzymatic degradation by peptidases in plasma and tissue, which tends to produce short circulating half-lives relative to small molecules.
• Low-molecular-weight peptides are generally subject to renal filtration, making kidney function a common determinant of systemic exposure.
• Injected peptides generally bypass first-pass gastrointestinal and hepatic degradation, whereas oral delivery of intact peptide is generally inefficient without a protective carrier.
• Metabolites of peptides are typically amino acids and short fragments that re-enter normal physiological pools, which is why peptide "clearance" often does not resemble small-molecule elimination.

Because these are field-level generalisations, they cannot be converted into an SS-31 half-life. Where a page elsewhere presents a generic peptide number as an SS-31 number, that substitution is the error.

Formulation and route: why a single number would not fit anyway

Even when a compound's intrinsic clearance is known, delivery format reshapes the exposure curve. Two papers in this set illustrate how far engineered delivery can shift timing. A 2026 study in Biomaterials described peptide coacervate–Prussian blue hybrid supraparticle-tailored scaffolds built to revitalise diabetic heart valve regeneration through multiplex oxidative stress regulation, an approach in which the active material is held at a site rather than distributed systemically (PMID 41145022). A 2025 review in the World Journal of Gastrointestinal Pharmacology and Therapeutics examined targeted nanoliposomal nutrient delivery as a strategy for altering how compounds are absorbed and distributed in human health applications (PMID 41378075). Neither paper reported SS-31 pharmacokinetics; both show that a carrier system can change residence time by design.

Factors the literature associates with altered clearance

Renal function

Kidney handling matters for small peptides as a class, and the SS-31 literature is heavily weighted toward renal models. The 2022 review reported that SS-31 ameliorated kidney disease in the models surveyed (PMID 35707274), and the 2025 Cells review described mitochondrial dysfunction as a catalyst of kidney disease progression (PMID 40497970). Impaired renal clearance is a plausible modifier of exposure on general pharmacological grounds; it has not been quantified for SS-31 in these papers.

Species and model

Rodent clearance is typically faster than human clearance for many compound classes, so timelines derived from mouse work — such as the diabetic mouse visual-decline models (PMID 26035391) — are not directly transferable to people.

Assay sensitivity

"Undetectable" always means undetectable by a particular assay at a particular limit of quantification. A more sensitive method can extend the apparent window without any change in physiology. This is why PK papers specify their analytical method, as the 2012 metoclopramide comparison did in defining single- and multiple-dose sampling in healthy male subjects (PMID 22328192).

Cumulative versus single exposure

Repeat administration changes the picture when dosing intervals are shorter than the elimination time; the 2012 study design separated single-dose from multiple-dose profiles precisely because those two curves differ (PMID 22328192). No equivalent multiple-dose accumulation analysis for SS-31 appears in the verified set.

Detectability and drug testing

Standard workplace drug screening panels are designed around a defined list of drugs of abuse — typically amphetamines, cannabinoids, cocaine metabolites, opiates and phencyclidine, with expanded panels adding benzodiazepines, barbiturates and similar classes. SS-31 is not a member of any of those classes and is not an analyte on those panels. A routine urine screen therefore does not look for it, and a negative or positive result on such a panel carries no information about it.

Research peptides are generally identified by targeted mass-spectrometry methods that must be developed and validated for each specific sequence, which means detection depends on a laboratory deliberately looking for that sequence. Anti-doping and clinical-research laboratories operate differently from workplace panels in this respect. The verified literature reviewed on this page does not address detection windows, anti-doping status or forensic assays for SS-31, and none is asserted here. Regulatory status is a separate matter from detectability: materials labelled research-use-only are not approved medicines, and that labelling says nothing about how long a compound persists biologically.

Adverse Events and Tolerability: What Studies Report

The SS-31 papers in this verified set are mechanistic and preclinical, and their abstracts centre on cellular and organ-level outcomes rather than on human safety endpoints. The 2021 disc-cell work reported effects on apoptosis and pyroptosis in nucleus pulposus cells (PMID 34903138), and the 2024 cardiomyopathy work reported effects on mitochondria-dependent ferroptosis (PMID 39364755); neither is a human tolerability trial, and no adverse-event rate, dose-limiting toxicity or discontinuation figure for SS-31 is available from the papers cited here. Broader reviews of mitochondria-directed strategies, including a 2026 review on targeting mitochondria for postoperative cognitive dysfunction, discussed the field as still moving from mechanism toward therapeutics (PMID 42570043), which is consistent with an incomplete human safety and pharmacokinetic record. Absence of reported harms in mechanistic papers is not evidence of safety.

How a researcher would close the gap

Answering the title question with a number would require a dedicated PK study in the relevant species and route, reporting C_max, T_max, half-life and AUC with a defined assay — the structure used in the 2012 metoclopramide comparison, which examined single and multiple dosing in healthy male subjects (PMID 22328192). Until such data for SS-31 are published and indexed, the accurate statement is that the compound's biological activity has been characterised in several disease models — renal (PMID 35707274), cardiac (PMID 39364755) and retinal (PMID 26035391) — while its clearance timeline in humans remains unquantified in the literature reviewed here.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision, and note that SS-31 is a research compound rather than an approved medicine.

Related reading

• SS-31: what the research literature describes
• How long do peptides stay in your system?

References

• SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease (Oxidative Medicine and Cellular Longevity, 2022)
• New insight for SS-31 in treating diabetic cardiomyopathy: Activation of mitoGPX4 and alleviation of mitochondria-dependent ferroptosis (International Journal of Molecular Medicine, 2024)
• The mitochondrial antioxidant SS-31 attenuated lipopolysaccharide-induced apoptosis and pyroptosis of nucleus pulposus cells via scavenging mitochondrial ROS and maintaining the stability of mitochondrial dynamics (Free Radical Research, 2021)
• A mitochondrial therapeutic reverses visual decline in mouse models of diabetes (Disease Models & Mechanisms, 2015)
• Mitochondrial Dysfunction: The Silent Catalyst of Kidney Disease Progression (Cells, 2025)
• Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure (Current Heart Failure Reports, 2017)
• Peptide coacervate-Prussian blue hybrid supraparticle-tailored scaffolds for revitalizing diabetic heart valve regeneration via multiplex oxidative stress regulation (Biomaterials, 2026)
• Targeted nanoliposomal nutrient delivery for human health (World Journal of Gastrointestinal Pharmacology and Therapeutics, 2025)
• Targeting Mitochondria for Postoperative Cognitive Dysfunction: From Mechanisms to Therapeutics (Molecular Neurobiology, 2026)
• Comparison of the pharmacokinetics of a new 30 mg modified-release tablet formulation of metoclopramide for once-a-day administration versus 10 mg immediate-release tablets: a single and multiple-dose, randomized, open-label, parallel study in healthy male subjects (European Journal of Drug Metabolism and Pharmacokinetics, 2012)